Simon Allen
Chief Executive Officer and Director
At Ambrx, Mr. Allen established multiple partnerships with companies including Bristol Myers Squibb, Pfizer, Merck, Eli Lilly, Astellas, BeiGene and Sino Biopharma that have generated more than $270 million in revenue with a potential $1 billion in future milestones and royalties. From 2016 to 2018 he was Chief Executive Officer of CohBar, where he transitioned the company from the preclinical to the clinical stage and managed the listing of its shares on Nasdaq, with subsequent inclusion in the Russell 2000 Index. Earlier Mr. Allen held various management, commercial and business development positions at Nuvelo, Skyepharma, CovX and Kalypsys.
Mr. Allen started his career as a research biologist in the antiviral group at Gilead Sciences before working in healthcare equity research and investment banking in the U.S. and Australia. He holds a BSc in biochemistry and genetics from the University of Sydney and an MBA from the Australian Graduate School of Management.
Dr. Kenneth Cundy, Ph.D.
Chief Scientific Officer
Sandra Gardiner
Acting Chief Financial Officer
Sandy Gardiner joined Anebulo in March 2023 as Acting Chief Financial Officer. Prior to joining Anebulo, Ms. Gardiner served as the Chief Financial Officer, Executive Vice President of Finance and Administration and Treasurer of Pulse Biosciences, Inc., a publicly traded medtech company (2019-2022). She also served as the Secretary of Pulse Biosciences from November 2019 until October 2021. She has held CFO roles in both domestic and global companies, operating as a director to international subsidiaries throughout Europe, Asia Pacific and Latin America. Her tenures include leadership positions at development-stage, pre-commercial to enterprise, and commercial $350M+ biotech and medtech companies. Ms. Gardiner has been involved in executing numerous financial transactions, including IPOs, secondary offerings, private placements, reverse mergers, rights offerings, ATMs and debt facilities.
Ms. Gardiner also served as Chief Financial Officer of Cutera, Inc., Tria Beauty, Inc., Aptus Endosystems, Inc., Ventus Medical, Inc., Vermillion, Inc., and Lipid Sciences, Inc. Earlier in her career, Ms. Gardiner served in roles of increasing responsibility at Cardima, Inc., Comac, Inc. and Advanced Cardiovascular Systems, Inc. Ms. Gardiner currently serves on the Board of Directors of LevitasBio and as Board Chair of the Valley Humane Society. She and previously served on the Board of Directors of Lucira Health Inc. including serving as Audit Committee Chair and a member of the Nominating and Corporate Governance Committee. Ms. Gardiner holds a Bachelor of Arts degree in Management Economics from the University of California, Davis.